Roche Reports Positive Phase I Results for Obesity Drug with 18.8% Weight Loss, Shares Gain 4.7%

May 16, 2024, 08:09 AM

Roche has reported positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity. The early-stage trial showed significant weight loss, with participants experiencing an 18.8% reduction in weight. Following this announcement, Roche shares gained 4.7% at the market open on Thursday. The results are seen as encouraging, especially as competition in the obesity drug market heats up. The drug, developed by the newly acquired Carmot Therapeutics, has shown faster results compared to existing treatments such as Wegovy.